In June 2017, Actelion became part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Actelion, headquartered in Allschwil, a town on the western suburb of Basel, Switzerland, is an industry leader in the field of pulmonary hypertension (PH), and most notably, pulmonary arterial hypertension (PAH). Its portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II to IV, with oral, inhaled and intravenous medications.
Over the past two decades, Actelion’s medicines have helped to significantly improve the prognosis and quality of life for people affected by PH.
Janssen has added PH as a therapy area of focus, to maintain and expand Actelion’s leadership position.
To learn more about PH, Actelion and its medicines, please visit www.actelion.com or follow @actelion_com.
Would you like to have comparative data on the burden of pulmonary heart disease across the world and by country? Do you need it from trusted sources? Find results easily among 3,500 epidemiological statistics and 140 indicators via the Janssen DiseaseLens™- your interactive health data tool.